SCHEMBL4403604

SCHEMBL4403604

COc1cc(OC)cc(-c2cc(=O)c3ccc(OCCCBr)cc3o2)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 4/20 0.62
ACHE P22303 4/20 0.62
MAOB P27338 2/20 0.59
KDM4E B2RXH2 2/20 0.58
ALDH1A1 P00352 2/20 0.58
CYP3A4 P08684 2/20 0.58
HPGD P15428 2/20 0.58
HSD17B10 Q99714 2/20 0.58
USP2 O75604 1/20 0.58
MAPK1 P28482 1/20 0.58
RECQL P46063 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
TNKS O95271 1/20 0.56
CYP19A1 P11511 1/20 0.56
MEN1 O00255 1/20 0.54
TP53 P04637 1/20 0.54
CYP2D6 P10635 1/20 0.54
MAPT P10636 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4405490 0.87 PABPC1 (0.63) BCHEACHEMAOB
SCHEMBL4399922 0.85 ABCB1 (0.72) BCHEACHEMAOBKDM4EALDH1A1
SCHEMBL4406416 0.81 MAOB (0.56) BCHEACHEMAOBKDM4EALDH1A1
SCHEMBL4411697 0.81 PABPC1 (0.64) BCHEACHEMAOB
SCHEMBL4039692 0.81 MAOB (0.73) BCHEACHEMAOBKDM4EALDH1A1
SCHEMBL11101571 0.80 BCHE (0.48) BCHEACHEMAOB
SCHEMBL13797866 0.78 MAOB (0.73) BCHEACHEMAOBKDM4EALDH1A1
SCHEMBL9199489 0.78 SIGMAR1 (0.72) KDM4ECYP3A4SMN1; SMN2TNKSCYP19A1
SCHEMBL4406405 0.77 SIGMAR1 (0.55) ACHEMAOBMAPT
SCHEMBL4404220 0.77 CYP3A4 (0.80) MAOBKDM4EALDH1A1CYP3A4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807408-B1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS COUNCIL SCIENT IND RES (IN) 2016-06-08 EP disclosed
US-7635779-B2 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2009-12-22 US disclosed
EP-1807408-A1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS Council of Scientific and Industrial Research (IN) 2007-07-18 EP disclosed
US-20060178373-A1 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2006-08-10 US disclosed
WO-2006040621-A1 OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178373-A1 Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents GPR119, LIPC, SLC5A2 BCHE 744/4885ACHE 1224/4885MAOB 518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.